Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll ...

What Happened? Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped in the afternoon session after UBS raised its price target on the company's stock to $81 from $76. The financial ...

Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...

If you are wondering whether Exponent is a bargain or a trap at today’s price, you are not alone. This breakdown is designed to help you see what the market might be missing. The stock has slipped 1.6 ...

Exponent's (NASDAQ:EXPO) stock up by 2.8% over the past month. Given its impressive performance, we decided to study the company's key financial indicators as a company's long-term fundamentals ...

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net ...

Earnings from consulting firm Exponent (NASDAQ: EXPO) came in below expectations, and the company continues to see challenges heading into 2024. Investors are moving to the sidelines, sending shares ...

Scientific consulting firm Exponent (NASDAQ:EXPO) will be announcing earnings results this Thursday afternoon. Here’s what to look for. Exponent beat analysts’ revenue expectations by 1.5% last ...

Fintel reports that on December 15, 2025, UBS maintained coverage of Exponent (NasdaqGS:EXPO) with a Neutral recommendation.